Solian

Solian contains amisulpride, a prescription antipsychotic medication indicated for adults diagnosed with schizophrenia by a qualified psychiatrist or mental health specialist. This selective dopamine receptor antagonist targets D2 and D3 subtypes, offering a distinct pharmacological profile for managing positive symptoms (hallucinations, delusions, thought disorders) and, at lower doses, negative symptoms (social withdrawal, flat affect) of schizophrenia.

Amisulpride represents a substituted benzamide class of atypical antipsychotics with selective binding properties that differentiate it from broader-spectrum agents. The medication requires careful dose titration and ongoing psychiatric supervision due to its effects on prolactin levels, potential metabolic impacts, and the need to monitor for extrapyramidal symptoms.

Solian is available through prescription channels with discreet delivery for patients under established psychiatric care in the US and Canada. Treatment should always occur within a comprehensive mental health management plan.

Key Benefits

• Selective dopamine D2/D3 receptor antagonism for targeted schizophrenia management
• Indicated for both acute psychotic episodes and chronic schizophrenic disorders
• Dose-dependent effects: higher doses (400-800mg) for positive symptoms, lower doses (50-300mg) for negative symptoms
• Available in multiple strengths (50mg, 100mg, 200mg, 400mg) for individualized treatment
• Atypical antipsychotic profile with specific receptor selectivity
• Factory-sealed pharmaceutical packaging for quality assurance
• Discreet international shipping for prescription holders

How It Works

Amisulpride functions as a selective antagonist at dopamine D2 and D3 receptor subtypes in the central nervous system. Unlike many antipsychotics that affect multiple neurotransmitter systems, amisulpride’s specificity lies in its preferential binding to these dopaminergic receptors without significant action on serotonin, histamine, or cholinergic pathways.

At therapeutic doses for positive symptoms (400-800mg daily), amisulpride blocks postsynaptic dopamine receptors in mesolimbic and mesocortical pathways, reducing excessive dopaminergic activity associated with hallucinations and delusions. At lower doses (50-300mg), it preferentially blocks presynaptic D2/D3 autoreceptors, potentially increasing dopamine release and addressing negative symptoms.

The medication’s poor lipid solubility limits blood-brain barrier penetration, requiring careful dosing to achieve therapeutic CNS levels. Bioavailability is approximately 48% following oral administration, with peak plasma concentrations occurring 3-4 hours post-dose [web:60]. Elimination occurs primarily via renal excretion of unchanged drug, with a terminal half-life of approximately 12 hours.

Indications

• Primary: Treatment of schizophrenia, including acute and chronic forms
• Positive symptoms: Hallucinations, delusions, thought disorders, agitation
• Negative symptoms (at lower doses): Social withdrawal, blunted affect, reduced motivation
• Note: Not approved for behavioral symptoms of dementia or off-label pediatric use

How to Use (General)

1. Obtain diagnosis and prescription from a licensed psychiatrist or mental health prescriber qualified to manage schizophrenia.
2. For acute psychosis: Typical starting dose 400-800mg daily divided into two doses; maximum 1200mg/day under specialist guidance.
3. For predominantly negative symptoms: Lower doses 50-300mg daily as directed.
4. Take tablets on an empty stomach when possible, as food may affect absorption.
5. Swallow tablets whole with water; scored tablets may be divided only if instructed by prescriber.
6. Attend regular monitoring appointments for blood tests (prolactin, glucose, lipids), blood pressure checks, and assessment of movement side effects.
7. Do not stop abruptly—taper only under medical supervision to avoid withdrawal symptoms.
8. Report any fever, muscle rigidity, confusion, or autonomic instability immediately (signs of neuroleptic malignant syndrome).

Side Effects

• Common: Insomnia, anxiety, drowsiness, weight gain, constipation, nausea, dry mouth, increased prolactin levels (may cause breast enlargement, galactorrhea, menstrual changes, erectile dysfunction)
• Extrapyramidal symptoms: Acute dystonia, parkinsonism (tremor, rigidity), akathisia (restlessness), tardive dyskinesia with prolonged use
• Metabolic effects: Hyperglycemia, increased triglycerides/cholesterol, increased diabetes risk in susceptible individuals
• Cardiovascular: QT interval prolongation, hypotension, bradycardia—requires ECG monitoring in at-risk patients
• Serious (seek immediate care): Neuroleptic malignant syndrome (fever, muscle rigidity, altered consciousness), seizures, sudden vision changes, severe allergic reactions, signs of blood disorders (unexplained infections, bruising)
• Elderly patients face increased fall risk due to drowsiness, confusion, and orthostatic hypotension

Interactions & Precautions

• Contraindicated with: Levodopa (reciprocal antagonism), pheochromocytoma, prolactin-dependent tumors (pituitary prolactinomas, certain breast cancers), children under 18
• Avoid concomitant use: QT-prolonging drugs (cisapride, certain antibiotics like erythromycin, antiarrhythmics, other antipsychotics), as this increases torsades de pointes risk
• Use caution with: CNS depressants (benzodiazepines, opioids, alcohol), antihypertensives (additive hypotension), lithium (increased neuroleptic toxicity risk
• Medical conditions requiring monitoring: Epilepsy/seizure history, Parkinson’s disease, cardiovascular disease, diabetes or pre-diabetes, renal impairment (dose reduction needed if CrCl <60 mL/min)
• Pregnancy Category: Not recommended—limited human data; neonatal withdrawal/extrapyramidal symptoms reported
• Breastfeeding: Contraindicated—amisulpride excreted in breast milk
• Driving/machinery: May impair alertness and motor coordination; assess individual response before operating vehicles

Storage

• Store below 25°C (77°F) in original packaging to protect from moisture and light
• Keep tablets in blister packs until use
• Out of reach of children and individuals not prescribed this medication
• Do not use past expiration date; dispose of unused medication via pharmacy take-back programs

Solian (Amisulpride) vs Other Antipsychotics

Disclaimer: This information is for educational purposes only and does not replace professional psychiatric evaluation. Solian (amisulpride) is a prescription antipsychotic requiring specialist oversight due to serious potential side effects including neuroleptic malignant syndrome, metabolic disturbances, and movement disorders. Not suitable for all patients with schizophrenia—individual risk-benefit assessment essential. Always consult a licensed psychiatrist before starting, adjusting, or stopping antipsychotic medication. Treatment should occur within comprehensive mental health care including psychosocial interventions.

References

• DrugBank: Amisulpride mechanism, pharmacokinetics, and clinical indications [link]​

• Wikipedia: Amisulpride approved uses and safety profile [link]​

• Sanofi Product Information: Solian tablets clinical particulars and dosing [link]​

• NPS MedicineWise: Patient-focused safety information for Solian [link]​

• PsychScene Hub: Amisulpride psychopharmacology and dosing strategies [link]​

• MIMS Singapore: Comprehensive prescribing information including contraindications [link]​